Idorsia Ltd (IDIA) Receives a Hold from Kepler Capital
In a report released on March 17, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), with a ...
US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients
Ad hoc announcement pursuant to Art. 53 LR FDA confirms that prescribers and pharmacists are no longer expected to interact ...
The Pharma Letter5d
Idorsia maintains momentum with Quviviq
The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...
Idorsia Pharmaceuticals Ltd: Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...
Idorsia Ltd (IDRSF) (Q4 2024) Earnings Call Highlights: Strategic Moves and Financial Resilience
Idorsia Ltd (IDRSF) reports significant growth in QUVIVIQ sales and successful debt restructuring, while navigating financial challenges and planning for future expansion.
Investing14d
Earnings call transcript: Idorsia sees reduced losses, strategic shifts in Q4 2024
Idorsia’s operating loss halved to CHF 308 million in 2024. QVIVIC sales nearly doubled, reaching CHF 61 million. The stock fell by 7.59% post-earnings. Strategic cost reductions included a ...
Seeking Alpha14d
Idorsia Ltd (IDRSF) Q4 2024 Earnings Call Transcript
Good day and thank you for standing by. Welcome to the Idorsia Full Year 2024 Financial Results Webcast. At this time, all participants are in listen-only mode. After the speakers' presentation ...